Novo Nordisk’s Semaglutide Tops Madrigal’s Rezdiffra In NASH
Greater Combined Effect Seen In Phase III Trials
The firm revealed that an analysis of its Phase III ESSENCE trial combining fibrosis reduction and NASH resolution showed a higher effect over placebo than in Madrigal’s pivotal trial.
